Skip to main content
Drug use among U.S. workers declined 74% over past 25 years According to new analysis Drug use among U.S. workers declined dramatically over the past 25 years, although the rate of positive test results for certain drugs, including amphetamine and opiates, continues to climb, according to an analysis of workplace drug test results released by Quest Diagnostics, a provider of diagnostic information services. The release of the special 25th anniversary Drug Testing Index (DTI) coincides with the anniversary of the passage of the Drug-Free Workplace Act in 1988. The Act requires federal contractors and all federal grantees to agree to provide drug-free workplaces as a precondition of receiving a contract or grant from a federal agency. Although the Act did not require mandatory drug testing, federal agencies subsequently promulgated drug testing regulations affecting "safety-sensitive" employees and other federal employees. Many private employers also created policies consistent with the federal requirements in order to minimize the hazards of drug use in the workplace. The DTI analysis examined more than 125 million urine drug tests performed by Quest Diagnostics forensic toxicology laboratories across the United States as a service for government and private employers between 1988 and 2012. The analysis examined the annual positivity rate for employees in positions subject to certain federal safety regulations, such as truck drivers, train operators, airline and nuclear power plant workers (federally mandated safety-sensitive workers); workers primarily from private companies (U.S. general workforce); and the results of both groups together (combined U.S. workforce). The index reports the percentage of results that tested positive for the presence of a drug or its metabolite, an adulterant, or that involved a specimen that was deemed to be unacceptable for testing ("positivity"). The company's testing services identify approximately 20 commonly abused drugs, including marijuana, opiates, and cocaine. Key findings from the analysis: • The positivity rate for the combined U.S. workforce declined 74 percent, from 13.6 percent in 1988 to 3.5 percent in 2012. • The positivity rate for the federally-mandated safety-sensitive workforce declined by 38 percent, from 2.6 percent in 1992 to 1.6 percent in 2012. • The positivity rate for the U.S. general workforce declined by 60 percent, from 10.3 percent in 1992 to 4.1 percent in 2012. • Despite the declines in overall drug use, the DTI analysis also found that the positivity rate for certain segments of drugs has increased. Positivity rates for amphetamines, including amphetamine and methamphetamine, has nearly tripled (196 percent higher) in the combined U.S. workforce and, in 2012, were at the highest level since 1997. The positivity rate for amphetamine itself, including prescription medications, has more than doubled in the last 10 years. Positivity rates for prescription opiates, which include the drugs hydrocodone, hydromorphone, oxycodone, and oxymorphone, have also increased steadily over the last decade - more than doubling for hydrocodone and hydromorphone and up 71 percent for oxycodone - reflective of national prescribing trends. This data is consistent with other studies, including a 2012 Quest Diagnostics Health Trends analysis of more than 75,000 test results from patients tested for compliance through the company's prescription drug monitoring services. This report found that the majority of Americans misused their prescription medications, including opioids and amphetamine medications. The DTI report also found that changing positivity rates often mirrored larger developments in drug use in the U.S. For instance, a decline in drug positives for methamphetamine observed in 2005 roughly coincided with federal and state efforts to crackdown on so-called "meth labs" and put over-the-counter medicines (such as ephedrine and pseudoephedrine) behind the pharmacy counter.

Popular posts from this blog

New Oxycodone Formula Gets Backing of FDA

The FDA recently voted in favor of pushing a new formulation of oxycodone hydrochloride for approval. The new OxyContin formula is more difficult to crush or dissolve which will hopefully make it harder to be used as a drug of abuse . The FDA recommended that Purdue Pharma's application for a new, resin-coated formulation should replace the original version, which has been on the market since 1996. Randall Flick, MD, an anesthesiologist at the Mayo Clinic who voted to recommend approval of the drug said, "Clearly the old formulation is worse than the new, although I think the difference is relatively small," Flick concluded, "Hardcore abusers are likely to devise new ways to break down the harder tablet or figure out which solvents will dissolve it fastest, within 'day or weeks' of the product's release on the market."

Utah Debates Drug Testing for Public Assistance

Utah has begun to follow the path that so many other states have traveled earlier this year. The path leads to drug testing for public assistance. Utah Senator Dennis Stowell had asked that the issue be studied carefully and Rep. Christopher Herrod said "If someone's on drugs, we shouldn't be giving them money," he said. "There's nowhere in the Constitution that says, 'You have a right to get welfare." At the center of the debate is cost and legality. An analyst for Community Action Partnership of Utah stated that "The cost to test all Utah’s families that receive 'Temporary Assistance for Needy Families' would be high." The analyst added, "That testing all welfare recipients just once would cost about $255,000 and a lawsuit against the state would likely cost more than $1 million." Further discussion and analysis is planned in the upcoming months to decide whether to study the issue further, table the issue or wait un

PHOTOS: MMC Through the Years

Mobile Medical Corporation (MMC) is excited to be celebrating our 30th Anniversary in 2020! MMC was founded on June 21, 1990. Check out some photos as we have grown over the years!